Publications by authors named "Thomas Voit"

Claim this Profile
P
Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real-world study.
Sabrina Sanfilippo, Ulrike Thurm, Mats Renfordt, Janis Schierbauer, Harald Sourij, Thomas Voit

Diabetes Obes Metab· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Low-To-Moderate Exogenous Carbohydrate Supplementation on Time to Exhaustion During Constant Load Intense Cycling in Healthy Individuals. A Double-Blind, Randomised and Placebo-Controlled Crossover Trial.
Janis Schierbauer, Oscar Altenberg, Thomas Voit, Paul Zimmermann, Othmar Moser

Eur J Sport Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations Between Clinical Inflammatory Risk Markers, Body Composition, Heart Rate Variability, and Accelerometer-Assessed Physical Activity in University Students with Overweight and Obesity.
Sascha W Hoffmann, Janis Schierbauer, Paul Zimmermann, Thomas Voit, Auguste Grothoff

Sensors (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Athlete Monitoring Systems in Elite Men's Basketball: Challenges, Recommendations, and Future Perspectives.
Jakob Burger, Alexander-Stephan Henze, Thomas Voit, Richard Latzel, Othmar Moser

Transl Sports Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of light-intensity physical activity on cardiometabolic parameters in young adults with overweight and obesity: The SED-ACT randomized controlled crossover trial.
Sascha W Hoffmann, Janis Schierbauer, Paul Zimmermann, Thomas Voit, Auguste Grothoff

Diabetes Obes Metab· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Interrupting Prolonged Sitting with Light-Intensity Physical Activity on Inflammatory and Cardiometabolic Risk Markers in Young Adults with Overweight and Obesity: Secondary Outcome Analyses of the SED-ACT Randomized Controlled Crossover Trial.
Sascha W Hoffmann, Janis Schierbauer, Paul Zimmermann, Thomas Voit, Auguste Grothoff

Biomolecules· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic Variability of LGMD 2C/R5 in a Genetically Homogenous Group of Bulgarian Muslim Roma.
Ani Taneva, David Gresham, Velina Guergueltcheva, Teodora Chamova, Veneta Bojinova, Thomas Voit

Genes (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Fluid Intake on Acute Changes in Plasma Volume: A Randomized Controlled Crossover Pilot Trial.
Janis Schierbauer, Sabrina Sanfilippo, Auguste Grothoff, Ulrich Fehr, Nadine Wachsmuth, Thomas Voit

Metabolites· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Different Types of Intermittent Fasting Interventions on Metabolic Health in Healthy Individuals (EDIF): A Randomised Trial with a Controlled-Run in Phase.
Daniel Herz, Sebastian Karl, Johannes Weiß, Paul Zimmermann, Sandra Haupt, Thomas Voit

Nutrients· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy.
Mathilde Sanson, Ai Vu Hong, Emmanuelle Massourides, Nathalie Bourg, Laurence Suel, Thomas Voit

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise.
Rebecca Tanja Zimmer, Alexander Auth, Janis Schierbauer, Sandra Haupt, Nadine Wachsmuth, Thomas Voit

Diabetes Technol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review.
Daniel Herz, Sandra Haupt, Rebecca Tanja Zimmer, Nadine Bianca Wachsmuth, Janis Schierbauer, Thomas Voit

Nutrients· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy.
Karen Anthony, Pierpaolo Ala, Francesco Catapano, Jinhong Meng, Joana Domingos, Thomas Voit

Hum Gene Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Fluid Intake Impacts Assessment of Body Composition via Bioelectrical Impedance Analysis. A Randomized, Controlled Crossover Pilot Trial.
Janis Schierbauer, Svenja Günther, Sandra Haupt, Rebecca T Zimmer, Daniel Herz, Thomas Voit

Metabolites· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A wearable motion capture suit and machine learning predict disease progression in Friedreich's ataxia.
Balasundaram Kadirvelu, Constantinos Gavriel, Sathiji Nageshwaran, Jackson Ping Kei Chan, Suran Nethisinghe, Thomas Voit

Nat Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.
Valeria Ricotti, Balasundaram Kadirvelu, Victoria Selby, Richard Festenstein, Eugenio Mercuri, Thomas Voit

Nat Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy.
Virginie Mariot, Romain Joubert, Laura Le Gall, Eva Sidlauskaite, Christophe Hourde, Thomas Voit

J Cachexia Sarcopenia Muscle· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International retrospective natural history study of -related congenital muscular dystrophy.
Rabah Ben Yaou, Pomi Yun, Ivana Dabaj, Gina Norato, Sandra Donkervoort, Thomas Voit

Brain Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial Distribution of a Porphyrin-Based Photosensitizer Reveals Mechanism of Photodynamic Inactivation of .
Thomas Voit, Fabian Cieplik, Johannes Regensburger, Karl-Anton Hiller, Anita Gollmer

Front Med (Lausanne)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy.
Fatima Amor, Ai Vu Hong, Guillaume Corre, Mathilde Sanson, Laurence Suel, Thomas Voit

J Cachexia Sarcopenia Muscle· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Virginie Mariot, Romain Joubert, Anne-Charlotte Marsollier, Christophe Hourdé, Thomas Voit

Mol Ther Nucleic Acids· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy.
Francesco Catapano, Dominic Scaglioni, Kate Maresh, Pierpaolo Ala, Joana Domingos, Thomas Voit

Epigenomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
Craig Campbell, Richard J Barohn, Enrico Bertini, Brigitte Chabrol, Giacomo Pietro Comi, Thomas Voit

J Comp Eff Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy.
Virginie Mariot, Caroline Le Guiner, Inès Barthélémy, Marie Montus, Stéphane Blot, Thomas Voit

Mol Ther Methods Clin Dev· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy.
Mathilde Sanson, Ai Vu Hong, Emmanuelle Massourides, Nathalie Bourg, Laurence Suel, Thomas Voit

Sci Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis